Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Teijin Limited
  6. News
  7. Summary
    3401   JP3544000007


Delayed Japan Exchange  -  02:00:00 2023-03-24 am EDT
1351.00 JPY   -0.22%
03/10Teijin : Notice Regarding Dividend Received from a Consolidated Subsidiary
03/06Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease
03/05Teijin : Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Teijin : Starts Exclusive Sales of Merzs Xeomin Botulinum Toxin Type A in Japan

12/04/2020 | 03:35am EDT

Tokyo, Japan --- Teijin Pharma Limited, the core company of the Teijin Groups healthcare business, announced today that it starts exclusive sales of Xeomin (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units on December 4 for the treatment of upper limb spasticity. The drugs have been listed in the National Health Insurance (NHI) drug price list on November 18.

Xeomin is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin to reduce the production of neutralizing antibodies capable of lowering efficacy. A significant improvement in the modified ashworth scale (MAS) score of wrist flexion was observed in the phase-III clinical trials in Japan.

Teijin Pharma signed an exclusive license and co-development agreement for Xeomin in Japan with Merz Pharma GmbH & Co. KGaA in 2017 and was granted approval by Japans Ministry of Health, Labor and Welfare (MHLW) to market it for the treatment of upper limb spasticity.

Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion, appearance of pathological reflexes, and sensory disturbances that complicate or impede activities in daily living.

Conventional treatment of upper limb spasticity includes physical rehabilitation and the use of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A.

Teijin Pharma already provides various pharmaceuticals including osteoporosis treatment and medical devices such as sonic accelerated fracture healing system that supports patients suffering from musculoskeletal diseases. The company has also developed motor functions rehabilitation products such as electric stimulation device and portable robotic arm that supports the rehabilitation of paralyzed upper limbs. Teijin Pharma continues to contribute to enhancing the quality of life (QOL) of patients by providing new treatment options for diseases with high unmet needs.

About Xeomin

Brand name

Xeomin 50 units for intramuscular injection

Xeomin100 units for intramuscular injection

Xeomin 200 units for intramuscular injection

Nonproprietary name incobotulinumtoxinA

Dosage form Injection (vial)

Indication Upper limb spasticity

Dosage and administration

In general, for adults, Xeomin should be injected into multiple tonic muscles.

* The maximum dose per administration is 400 units, however, the dose should be appropriately reduced to the minimum depending on the type and number of targeted tonic muscles. Repeated doses are permissible if the effect of a previous dose diminish. The dosing interval should be 12 weeks or longer, but may be shortened to 10 weeks depending on the symptoms.

*Tonic muscles: flexor carpi radialis, flexor carpi ulnaris, flexor digitorum dorsi, flexor digitorum brevis, radial biceps, biceps brachii, brachial musculature, pronation of the pronator, flexor progenitor, flexor pollicis longus, adductor pollicis longus, flexor pollicis brevis/opposite thumb muscle, etc.

Xeomin is the registered trademark of Merz Pharma GmbH & Co. KGaA.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement Human Chemistry, Human Solutions, Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.

Please visit www.teijin.com


(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

All news about TEIJIN LIMITED
03/10Teijin : Notice Regarding Dividend Received from a Consolidated Subsidiary
03/06Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candid..
03/05Teijin : Pharma Grants Global Exclusive License for Investigational Small Molecule Candida..
02/19Teijin : and Axcelead, Inc. to Establish Drug Discovery Research JV
02/10Teijin : Named "Excellent Company for Sustainability" by S&P Global
02/09Federal Reserve Outlook, Softer Yen Roil Tokyo Stock Market
02/08Transcript : Teijin Limited - Special Call
02/07Teijin : Notice Regarding the Revision of Financial Forecasts and the Recording of Extraor..
02/07Transcript : Teijin Limited, Q3 2023 Earnings Call, Feb 08, 2023
02/07Teijin Limited Provides Dividend Guidance for the Fourth Quarter of Fiscal Year 2022
More news
Sales 2023 1 028 B 7 864 M 7 864 M
Net income 2023 -7 143 M -54,6 M -54,6 M
Net Debt 2023 347 B 2 651 M 2 651 M
P/E ratio 2023 -36,3x
Yield 2023 2,96%
Capitalization 260 B 1 986 M 1 986 M
EV / Sales 2023 0,59x
EV / Sales 2024 0,58x
Nbr of Employees 21 815
Free-Float 92,0%
Duration : Period :
Teijin Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEIJIN LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 7
Last Close Price 1 351,00 JPY
Average target price 1 485,00 JPY
Spread / Average Target 9,92%
EPS Revisions
Managers and Directors
Akimoto Uchikawa President, CEO & Representative Director
Akihisa Nabeshima Chief Financial Officer & Representative Director
Jun Suzuki Chairman
Taizo Makari Executive Officer & Head-Engineering
Yukako Uchinaga Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
K.P.R. MILL LIMITED11.19%2 384
COATS GROUP PLC12.54%1 455
Stock markets for all
100% Free Registration